UK markets closed

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
43.75+0.75 (+1.74%)
At close: 04:00PM EDT
43.75 0.00 (0.00%)
After hours: 05:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close43.00
Open43.58
Bid43.66 x 100
Ask43.85 x 100
Day's range42.87 - 43.79
52-week range27.99 - 50.99
Volume234,306
Avg. volume369,813
Market cap3.302B
Beta (5Y monthly)1.18
PE ratio (TTM)N/A
EPS (TTM)-2.73
Earnings date09 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est58.10
  • GlobeNewswire

    Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update

    VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, May 9, 2024. Conference Call/Webcast Information: Date:Thursday, May 9, 2024 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast:Pre-register here Dial-In: (800) 715-9871 toll-free, or (646) 307-1963

  • GlobeNewswire

    Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting

    VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are excited that our abstracts focused on XEN1101, including interim data from the ongoing X-TOLE open-label extension st

  • GlobeNewswire

    Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

    VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16-17, 2024. Company Presentation Details:Date: Tuesday, April 16, 2024Time: 9:30 AM Eastern TimeWebcast: Register herePresenters: Ian Mortimer, President and Chief Executive Officer A live webcast of the company present